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EXCITATORY amino acids have been implicated as
important mediators in the process of neuronal cell
death in hypoxia, ischaemia and chronic neurodegen-
erative diseases (Choi et al., 1995; Coyle & Puttfarken,
1993; Dodd et al., 1994; Maragos et al., 1987; Rothman
& Olney, 1986). During cerebral ischaemia excessive
release of the excitatory neurotransmitter glutamate is
observed (Benveniste et al., 1984), which leads to an
uncontrolled rise of intracellular free Ca21 (Dubinsky,
1993) and ultimately to neuronal necrosis (Randall &
Thayer, 1992). Massive entry through various chan-
nels of Ca21 into neurons is considered to be the final
common pathway leading to irreversible neuronal
damage, since persistent high levels of cytosolic free
Ca21 may evoke dysregulations of Ca21 activated
processes which are detrimental to neurons (Clapham,
1995). Both N-methyl-D-aspartate (NMDA) receptor-
operated ion channels and voltage-dependent Ca21
channels (VDCCs) appear to be largely responsible for
the massive Ca21 influx during excitotoxic insults
(Garcia et al.,1994; Hartley et al.,1993; Lobner & Lipton,
1993; Rothman & Olney, 1995). During the initial phase
of ischaemia Ca21 influx is shown to be mediated pri-
marily by stimulated NMDA-channels followed by a
secondary influx involving other Ca21 channels
(Lobner & Lipton, 1993) activated by voltage changes
or intracellular messenger systems (Chetkovich et al.,
1991; Garcia et al., 1994; Skeen et al., 1994). Agents that
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Neuroprotection against excitotoxicity by a combined therapy with the N-methyl-D-aspartate
(NMDA) receptor antagonist MK-801 and the L-type Ca2+ channel blocker nimodipine was exam-
ined using an in vivo rat model of NMDA-induced neurodegeneration. Attention was focused on
the neuroprotective potential of this combined drug treatment before and after NMDA-exposure.
NMDA was unilaterally injected in the magnocellular nucleus basalis (MBN). Neuronal damage
was assessed 12 days after the NMDA-injection by measuring the reduction of cholinergic corti-
cal fibres that originate from the MBN neurons. In controls that received no drug treatment,
NMDA-exposure damaged MBN neurons such that 66% of the cholinergic terminals were lost in
the ipsilateral parietal cortex. Pretreatment with a nimodipine diet (860 ppm) combined with
application of MK-801 (5 mg/kg i.p.) before NMDA-exposure reduced fibre loss by 89% thereby
providing a near complete neuroprotection. Combined therapy of MK-801 (5 mg/kg i.p.) and
nimodipine (15 mg/kg i.p.) 8 min after NMDA-infusion reduced neuronal injury by 82%, while
the same combination given 2 h after the excitotoxic treatment still yielded a 66% protection
against neurotoxic damage invoked by NMDA. In conclusion, the present data show that a dual
blockade of NMDA-channels and voltage-dependent calcium channels (VDCC's) up to 2 h after
NMDA-exposure is able to provide a significant protection against NMDA-neurotoxicity.
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block the Ca2+ entry through activated NMDA-chan-
nels have been demonstrated in several ischaemia
model studies to decrease neuronal damage (Gill et al.,
1987; Meldrum & Garthwaite, 1990; Siesjö et al., 1992).
Other reports indicate that also blockade of the VDCCs
and notably the L-type channels by dihydropyridines
provide a remarkable neuroprotection in experimen-
tal ischaemia (Bellemann et al., 1983; Langley & Sorkin,
1989; Nuglisch et al., 1990; Rami & Krieglstein 1994;
Scriabine et al., 1989). 
In the present study we evaluated combined treat-
ment with a noncompetitive NMDA-receptor antago-
nist (MK-801) and a voltage dependent L-type Ca21
channel blocker (nimodipine) for its neuroprotective
effects against NMDA-induced neuronal injury. 
Both MK-801 (dizocilipine) and nimodipine (a 1,4-
dihydropyridine derivate, BAY E 9736) have been
demonstrated to attenuate brain injury following
experimental ischaemia and excitotoxic insults (Gill 
et al., 1987; Luiten et al., 1995; McDonald et al., 1990;
Nakamura et al., 1993; Nuglisch et al., 1990). 
In the currently used model NMDA was unilater-
ally injected in the cholinergic cell groups of the mag-
nocellular nucleus basalis (MBN), which have axonal
projections to the ipsilateral cortex (Fig. 1). Neuronal
injury was measured on the reductions of cholinergic
axonal fibres in the injected hemisphere, whereby the
cholinergic innervation of the intact contralateral side
served as internal control. In our previous study this
in vivo model was proven to be very suitable and reli-
able for quantitative assessment of neuroprotective
properties of potentially beneficial agents (Luiten et al.,
1995). 
First we examined dose dependent neuroprotective
effects of pretreatment with MK-801 to select an appro-
priate dose for testing a combined therapy with
nimodipine. Secondly the neuroprotective impact of
the combination therapy was compared to the effects
of single drug treatments with MK-801 and nimodip-
ine. Finally we investigated the temporal course of
neuroprotection, by measuring the degree of neuro-
protection of both drugs applied at several time points
before and after NMDA-exposure.
Materials and Methods
Subjects and treatments
The experiments of the present study were carried out on a
total of 51 young adult (3 month old) male Wistar rats (aver-
age body weight 320 g) bred in our own facilities. The ani-
mals were housed at a standard temperature of 23 6 1°C in
a light controlled room (lights on from 07.00 h to 19.00 h).
All rats had free access to either standard food pellets (Sniff,
Soest, FRG) or (in case of nimodipine treatment) to identical
pellets containing nimodipine at a concentration of 860 ppm. 
Animals were divided and allocated to two experiments.
In the first experiment the neuroprotective effects of three
different doses MK-801, applied 2 h before NMDA-infusion,
were determined to select an appropriate dose for testing a
combined treatment with nimodipine. In the second exper-
iment the neuroprotective effects of a combined therapy
with MK-801 and nimodipine were compared with the
effects of single treatments with either of these drugs against
NMDA-neurotoxicity. To study the temporal profile of
potential neuroprotection, in the latter experiment com-
bined and single drug therapy was also applied 8 min and
2 h after NMDA-injection. These time points were chosen
based on previous reports, studying the temporal course of
excitoxicity processes due to NMDA exposure, showing an
initial calcium influx within 30 min after NMDA-application
(Van Lookeren Campagne et al., 1994; Tymianski et al., 1993).
The 8 min interval was chosen for practical reasons. At this
moment the animals could be removed from the stereotaxic
frame, so that a proper i.p. injection could be performed.
Experiment I 
To study the effects of three different doses MK-801 on
NMDA-induced neuronal injury, 22 animals were divided
into four groups: (1) controls with NMDA-injections in the
MBN, but receiving no drug treatment at all (n 5 6); (2) rats
receiving 1 mg/kg MK-801 (n 5 5); (3) rats receiving 3
mg/kg MK-801 (n 5 6); and (4) a group of animals receiv-
ing 5 mg/kg MK-801 (n 5 6). MK-801 was dissolved in phos-
phate buffered saline, pH 7.4 (PBS) and i.p. injected 2 h before
NMDA-infusion. The controls of the first experiment also
served as controls for the second experiment.
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Figure 1. The position of the needle in the MBN, also illus-
trating cholinergic cell bodies and an axonal fibre projection
to the cortex. Abbreviations: Cx, cortex; CPu, caudate puta-
men; MBN, magnocellular nucleus basalis.
Experiment II 
From the results of the first experiment the dose of 5 mg/kg
MK-801 was selected for further study of the neuroprotec-
tion by a combined therapy of MK-801 and nimodipine. For
investigating the temporal course of protection, besides pre-
treatment, drugs were applied 8 min and 2 h after NMDA-
exposure in different groups. For pretreatment with
nimodipine, rats received food pellets containing 860 ppm
nimodipine starting 2 weeks prior to NMDA-injection. The
concentration 860 ppm was chosen because it was shown in
a number of studies to be an optimal dose yielding neuro-
protective effects (Schuurman et al., 1987; Scriabine et al.,
1989; De Jong et al., 1992), without affecting brain metabo-
lism (Harper et al., 1981), blood pressure or circulation para-
meters (Kazda et al.,1985). During the period of nimodipine
application in food, the daily food intake was measured.
Posttreatment with nimodipine consisted of an 15 mg/kg
i.p. injection with nimodipine dissolved in a mixture of
ethanol and polyethylene glycol (2:1). The various groups in
experiment II are summarized in Table 1.
Surgical procedure
Excitotoxic damage to the MBN in all cases was carried out
unilaterally in the right hemisphere, such that the intact left
hemisphere served as a control for each individual case. The
animals were anaesthetized with a combination of sodium
pentobarbital (30 mg/kg i.p.) and hypnorm (Duphar, Weesp,
Netherlands, 0.4 mg/kg i.m.). The anticholinergicum
atropine-sulphate (0.5 mg/kg i.p.) was used to limit salivary
bronchial secretion. Rats were positioned in a stereotaxic
frame, the head skin was retracted and a small hole was
drilled in the skull. For the toxin injections a 5 m l Hamilton
syringe was positioned in the MBN at the coordinates 1.5
mm posterior to bregma and 3.2 mm lateral to the midline
(defined by the atlas of Paxinos & Watson, 1986). At two
dorso-ventral positions, 6.2 mm and 7.0 mm ventral to the
dura, 0.5 m l PBS containing 30 nmol of a racemic mixture of
N-methyl-D,L-aspartate (Sigma, St. Louis) was slowly
injected in steps of 0.1 m l, so that a total of 60 nmol was
injected in the MBN. After each injection the needle was left
in situ for 5 min to allow for diffusion and to limit spread of
the toxin solution during withdrawal of the needle. The dose
of 60 nmol was shown in a previous study (Luiten et al., 1995)
to result in a 66% reduction of cholinergic fibres projecting
to the ipsilateral cortex. Therefore this dose was considered
as suitable for studying neuroprotective potentials of the
used compounds. After surgery, all animals survived for 12
days until sacrifice and histological processing.
Tissue processing and histochemistry
Fixation of the brain was carried out by transcardial perfu-
sion with 300 ml fixative composed of 2.5% paraformalde-
hyde, 0.05% glutardialdehyde and 0.2% picric acid in 0.1 M
phosphate buffer (PB, pH 7.4) at a perfusion speed of 20
ml/min, which was preceded by a short prerinse of
heparinized saline. The brains were removed from the skull
and cryoprotected by overnight storage at 4°C in 30%
sucrose in 0.1 M PB. Subsequently, the brains were coronally
sectioned on a cryostat microtome at a thickness of 20 m m.
Before sectioning, the left hemisphere (control side) was
marked by punching a small needle hole in the corpus cal-
losum. The free floating brain sections were postfixed by
immersion in a 2.5% glutardialdehyde solution in PBS
overnight at 4°C. Hereafter, the cholinergic fibres were visu-
alized by staining for the presence of acetylcholinesterase
(AChE) according to Hedreen et al. (1985) using a silver-
nitrate intensification procedure. Finally, the sections were
mounted, dehydrated, cover-slipped and examined by light
microscopy.
To determine the effect of the neuronal injury in the MBN,
the cholinergic fibre density was measured in layer V of the
posterior somatosensory cortex in both the left (control side)
and right (injection side) hemispheres. Fibre densities were
assessed by means of counting fibre crossings with the lines
of an in-built ocular counting grid, described in detail by
Luiten et al. (1995). Crossing fibres were counted in three sec-
tions, representing a cortical region receiving the densest
cholinergic innervation from the damaged MBN division
(Luiten et al., 1987). Comparison between the counted fibre
crossings at the injected side and counted values at the intact
control side revealed the percentage fibre reduction, which
was considered to be proportional to the degree of neuro-
toxic cell damage. This way a relative value was obtained
that was insensitive to individual variations between cases
that might occur for technical or other reasons. Percentage
neuroprotection for each experimental drug treatment was
calculated by the ratio of fibre reduction after NMDA-injec-
tion with [X] and without drug application [C], according to
the following formula: 
% protection 5 100(1-(% fibre reduction [X]/% fibre reduc-
tion [C]))
Statistical analysis
To examine a dose-dependent influence of MK-801 on fibre
reduction after NMDA-induced injury one-way analysis of
variance (ANOVA) was performed. ANOVA was carried out
also to define the temporal profile of neuroprotection by
combined therapy with nimodipine and MK-801. The non-
parametric Mann-Whitney-U test (STATS program) was
used for comparison between the effects of the different
treatments on fibre reduction after neurotoxic injury of the
MBN. A P value less than 0.05 was considered to indicate
statistical significance. Data are presented as mean 6 stan-
dard error of the mean (SEM).
Neuroprotection by MK-801 and nimodipine 155
Table 1. Summary of the different drug treatments in
experiment II against NMDA-toxicity
Pretreatment Posttreatment
8 min 2 h
Nimodipine n 5 6 n 5 7 n 5 6
MK-801 n 5 6 n 5 6 n 5 6
Nimodipine 1
MK-801 n 5 6 n 5 8 n 5 6
Results
Experiment I
Unilateral injections of NMDA in the MBN complex
of non-drug treated animals (controls) resulted in a
profound decrease of cholinergic fibres in a large part
of the ipsilateral cortex, corresponding with the uni-
laterally organized anatomical pattern of MBN pro-
jections to the cortex in the rat. In the majority of the
animals NMDA induced seizures which appeared
after surgery when consciousness was regained. The
seizures disappeared again within 2 h. A 66.2 6 3.3%
reduction of fibre density was measured 12 days after
the NMDA-infusion. All doses of MK-801 applied 2 h
before MBN injection significantly attenuated NMDA-
induced cortical fibre reduction compared to controls
(P , 0.01, Fig. 2). Fibre loss was reduced in a dose-
dependent way (one-way ANOVA P , 0.001). The
dose of 1 mg/kg MK-801 revealed a neuroprotection
of 37.7%, while for 3 mg/kg and 5 mg/kg MK-801 
neuroprotection was calculated as 46.0% and 72.3%,
respectively. 
Experiment II
The dose of 5 mg/kg MK-801 from the first experiment
was selected for further investigating a combined
treatment of MK-801 and nimodipine. In case of
nimodipine application in food pellets (860 ppm), food
intake ranged from 20 to 26 g/day, which signified a
daily nimodipine intake of 17 to 22 mg. Treatment with
a nimodipine diet starting two weeks before NMDA-
infusion attenuated the NMDA-induced cortical fibre
reduction from 66.2 6 3.3% (controls) to 47.2 6 5.6%
(P , 0.01), providing a neuroprotection of 28.8% (Fig.
3, Table 2).
Combination of pretreatments of MK-801 together
with nimodipine potently antagonized NMDA-
induced neuronal injury and subsequent cholinergic
fibre decline. Denervation values were strikingly
reduced to only 6.7 6 1.5% (P , 0.01 vs control) and
approached our previously found fibre reductions
(4.7%) in sham operated animals infused with vehicle
solution (Luiten et al., 1995). The neuroprotective
effects of the combined treatment were significantly
higher (P , 0.01) than the effects of single drug treat-
ments. Application of nimodipine together with MK-
801 yielded a protection of 89.4% against the
excitotoxic effects of NMDA. Concerning single drug
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Figure 2. The effect of three different dosages MK-801 on
percentage fibre loss 12 days after injection of NMDA in the
MBN. MK-801 was injected 2 h prior to the injection of
NMDA. Controls received no drug-treatment before NMDA
infusion. Values are means (6 SEM) of 5–6 animals in each
group and analysed using the non parametric Mann-
Whitney-U-test; P , 0.01 for all MK-801 doses vs Control. 
Table 2. Percentage fibre loss (6SEM) after NMDA-exposure and calculated neuropro-
tection (between brackets) by single and combined pre-/posttreatment with nimodipine
and MK-801
Pretreatment Posttreatment
8 min 2 h
Nimodipine 47.2 6 5.6% (29%) 38.4 6 3.5% (42%) 59.8 6 4.1% (10%)ns
MK-801 18.3 6 0.9% (72%) 17.7 6 2.3% (73%) 30.0 6 2.6% (55%)
Nimodipine 1
MK-801 6.7 6 1.5% (89%) 12.0 6 0.7% (82%) 22.9 6 1.2% (66%
Control 66.2  6 3.3% (0%)
ns not significant; for all other values P , 0.01 vs control.
therapy, protective effects of posttreatment 8 min after
NMDA-exposure were not significantly different from
the effects of pretreatment. However, combined treat-
ment with nimodipine and MK-801 pretreatment was
significantly (P , 0.01) more effective than treatment
8 min after NMDA-injection. With regard to the start
of the combined therapy or single drug application of
nimodipine (15 mg/kg i.p.) and MK-801 (5 mg/kg i.p.)
after NMDA-injection, the degree of protection
showed a time-dependent effect (ANOVA, P , 0.01).
Combined nimodipine/MK-801 treatment 8 min
after NMDA-injections revealed 81.9% protection.
Application 2 h later resulted in significantly more
fibre loss but protection values still measured up to
65.5%. Single drug treatments showed significantly
lower protective results at both time points (P , 0.01).
It was noteworthy that nimodipine alone applied 2 h
after NMDA-exposure revealed no significant protec-
tion, whereas combined with MK-801 it resulted in
significantly (P , 0.01) higher protection values com-
pared to single MK-801 application.
Discussion
In the present study we demonstrated that the com-
bined therapy with a non-competitive NMDA-antag-
onist (MK-801) and an L-type VDCC blocker
(nimodipine) exerted an additional protective
influence against NMDA-induced toxicity to cholin-
ergic neurons in the nucleus basalis. The additional
protective effect of MK-801 and nimodipine has also
been reported in models of ischaemia and in tissue
trauma in culture (Greenberg et al., 1990; Rod & Auer,
1992; Uematsu et al., 1991; Regan & Choi, 1994).
Furthermore, the degree of protection showed a time-
dependent effect with regard to the start of the drug
treatment after the NMDA-injection.
A 73% protection achieved by the highest MK-801
dose (5 mg/kg) applied before NMDA-injection was
further increased to 89% by additional nimodipine
treatment. In a previous study we already showed that
nimodipine treatment prior to NMDA-exposure pro-
vided almost 30% neuroprotection indicating the
involvement of activated VDCCs in the NMDA-
induced neurodegenerative process (Luiten 
et al., 1995). The present data suggest that also in case
of a strong neuronal protection against NMDA-
induced neuronal damage by NMDA-antagonists,
simultaneous blockade of VDCC-mediated Ca21 cur-
rents can additionally and significantly inhibit the
process of neuronal damage. 
In the initial phase of NMDA-overstimulation as in
ischaemic conditions Ca21 influx depends primarily
on NMDA-channels (Bading et al., 1995; Garcia et al.,
1994). There are good arguments that secondary Ca21
currents through activated VDCC are involved in the
later stages of NMDA-induced cell damage (Garcia et
al., 1994; Lobner & Lipton, 1993). Several mechanisms
may underlie increase of Ca21 currents through
VDCCs after overstimulation by NMDA. Firstly,
membrane depolarization caused by NMDA-channel
activation can trigger additional Ca21 influx through
neighbouring VDCCs (Skeen et al.,1993). Intracellular
messenger systems, including cAMP associated path-
ways, are thought to be involved in the delayed long-
term enhancement of voltage-gated Ca21 currents after
NMDA-receptor stimulation (Chetkovich et al., 1991;
Garcia et al., 1994; Mironov & Lux, 1992).
Pretreatment with MK-801 and nimodipine yielded
a neuroprotection of 89% while application of this
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Figure 3. The effect of single and combined pre-/post-
treatment with nimodipine  and MK-801 on percentage fibre
loss 12 days after injection of NMDA in the MBN. Controls
received no drug-treatment before and after NMDA-expo-
sure. Nimodipine pretreatment consisted of a nimodipine
diet (860 ppm), while posttreatment existed of an i.p. injec-
tion with nimodipine (15 mg/kg). MK-801 (5 mg/kg) was
i.p. injected. (h) control; ( ) nimodipine; ( ) Mk-801; (j)
nimodipine 1 Mk-801. Values are means (6SEM) of 6–9 ani-
mals in each group and analyzed using the non parametric
Mann-Whitney-U-test; P , 0.05 for each therapy vs
Control, except for Nimo vs Control 2 h posttreatment (P 5
0.07).
drug combination 8 min and 2 h after injection gener-
ated a protection of 82% and 66%, respectively. Based
on these observations it may be concluded that up to
2 h after NMDA-injection a blockade of NMDA-recep-
tor- and VDCC-mediated Ca2+ currents is able to pro-
tect the majority of neurons against NMDA-induced
neurotoxicity. However, these results also indicate that
a part of the neurons which benefit from protection by
nimodipine and MK-801 when these drugs are given
before and shortly after (8 min) the neurotoxic event,
cannot be prevented from neuronal death by the drug
application 2 h after NMDA-injection. Early neurotox-
icity during the first 2 h after NMDA-exposure,
exerted by the initial massive Ca21 influx may explain
this early irreversible cell damage. Studies in which
single neurons in culture were lethally challenged
with excitatory amino acids showed an initial Ca21
influx through NMDA-channels followed by a
delayed secondary, sustained and irreversible Ca21
rise indicating imminent cell death (Randall & Thayer,
1992; Tymianski et al., 1993). Early blockade of Ca21
influx by NMDA-antagonists was able to prevent this
early cell death (Hartley et al., 1993; Tymianski et al.,
1993). An initial massive Ca21 transient is considered
also to be a critical step in triggering delayed neuronal
death. Blockade of NMDA-channels may thus provide
the highest degree of neuroprotection in the early
phase of excitotoxicity. However, it appears in our cur-
rently used in vivo excitotoxicity model that still more
than 60% protection can be achieved by blockade of
NMDA- and voltage-dependent Ca21 currents at 2 h
after NMDA-infusion. 
Other in vivo studies have also reported a striking
neuroprotection by MK-801 alone when applied sev-
eral hours after NMDA-exposure (Foster et al., 1987;
Van Lookeren Campagne et al., 1994). It seems likely
that in particular neurons in the centre of the NMDA-
injection site, where the NMDA-concentration is high-
est, will be irreversibly affected by an initial
NMDA-mediated massive Ca21 influx. By diffusion
NMDA will reach other neurons in a later stage and a
lower concentration. Therefore remaining majority 
of neurons may be affected by slow and reversible 
neurotoxic processes involving Ca21 influxes through
activated VDCCs and NMDA-channels. Currently,
time dependent regional calcium accumulation is
investigated in our NMDA-toxicity model by 45Ca-
autoradiograpy, to elucidate the time-dependent
process of excitotoxic damage in the NBM.
Based on the observations of delayed enhancement
of voltage-dependent Ca21 currents after NMDA-
overstimulation (Randall & Thayer, 1992; Tymianski
et al., 1993), we would expect a longer lasting neuro-
protective potential of nimodipine. Surprisingly,
nimodipine alone applied 2 h after NMDA-exposure
revealed no significant neuroprotection, compared to
a still strongly protective effect established by MK-801.
This finding demonstrates that at this stage of excito-
toxic insult blockade of activated NMDA-channels is
more effective in inhibition of NMDA-neurotoxicity
than antagonizing L-type Ca21-channels. These obser-
vations suggest that mainly activated NMDA-chan-
nels are involved in the later stages of NMDA-induced
neurotoxic processes. However, in this period of
delayed cell death nimodipine combined with MK-801
was able to reduce neuronal damage to a significantly
higher level compared to the protective effects of MK-
801 alone. Presumably, during single NMDA-receptor
blockade [Ca21]i will still reach lethal levels in some
neurons, which can be prevented by an additional
VDCC blockade. More detailed analysis of the cy-
tology of cellular damage in the injected region, as 
currently investigated by us, is necessary to material-
ize these assumptions.
In conclusion, the present data show that dual 
blockade of NMDA-channels and VDCCs reveals an
additional neuroprotective effect against NMDA-
neurotoxicity. The degree of neuroprotection by this
therapy is slowly decreased concomitant with the
delay of application after NMDA-injection. Early
treatment with this drug combination will yield opti-
mal neuroprotection by blocking an initially triggered
influx of Ca21. However, by dual blockade of both
classes of Ca21-channels after this initial phase of Ca21-
overload, there is still a significant potential for revers-
ing NMDA-induced neurotoxic processes.
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